

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

ring/chain bonds :

11-16

ring bonds :

1-2 1-6 1-12 2-3 2-14 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 10-11 12-13 13-14
15-17 15-16 16-20 17-18 18-19 19-20

exact/norm bonds :

1-2 1-6 1-12 2-3 2-14 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 10-11 11-16 12-13
13-14 15-17 15-16 16-20 17-18 18-19 19-20

G1:C,N

G2:C,O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom

10/649,495

=> d his

(FILE 'HOME' ENTERED AT 11:52:45 ON 18 APR 2006)

FILE 'REGISTRY' ENTERED AT 11:54:28 ON 18 APR 2006
L1 STRUCTURE uploaded

L2 0 S L1
L3 26 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 11:55:01 ON 18 APR 2006

L4 2 S L3
L5 1 S US20040058906/PN
 SELECT RN L5 1-

FILE 'REGISTRY' ENTERED AT 11:55:35 ON 18 APR 2006


L6 76 S E1-76
L7 31 S L6 AND NRS=1
L8 29 S L6 AND NRS>1
L9 16 S L6 NOT (L7 OR L8)
L10 59174 S 5-6-7/SZ
L11 10 S L8 AND L10
L12 19 S L8 NOT L11
L13 1 S L12 AND 5-6-6-6-7/SZ
L14 18 S L12 NOT L13
L15 11 S L8 NOT L14
L16 12 S L7 AND 5-6-6-6-7/SZ
L17 19 S L7 NOT L16
L18 23 S L15 OR L16
L19 21 S L3 AND L18
L20 2 S L18 NOT L19
L21 STRUCTURE uploaded
L22 0 S L21
L23 29 S L21 SSS FUL

FILE 'CAPLUS' ENTERED AT 12:03:22 ON 18 APR 2006

L24 2 S L23

=> d l21

L21 HAS NO ANSWERS
L21 STR



G1 C,N


G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.


=> d ibib abs hitstr total

10/649,495


L24 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:31564 CAPLUS
DOCUMENT NUMBER: 142:316682
TITLE: Dopamine D₁/D₅ Receptor Antagonists with Improved Pharmacokinetics: Design, Synthesis, and Biological Evaluation of Phenol Bioisosteric Analogues of Benzazepine D₁/D₅ Antagonists
AUTHOR(S): Wu, Wen-Lian; Burnett, Duane A.; Spring, Richard; Greenlee, William J.; Smith, Michelle; Favreau, Leonard; Fawzi, Ahmad; Zhang, Hongtao; Lachowicz, Jean E.
CORPORATE SOURCE: Schering-Plough Research Institute, Kenilworth, NJ, 07033, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(3), 680-693
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:316682
GI



I



II



III

AB Nonracemic fused benzazepines and naphthazepines such as I (R = H, Me) are prepared as selective dopamine D₁ and D₅ receptor antagonists with improved bioavailability over related high affinity dopamine D₁ and D₅ receptor antagonists by replacement of the phenol moiety in II (X = CH₂CH₂) with a variety of fused hydrogen-bond donating moieties. Benzazepines in which the hydrogen bond donor is pointed approx. parallel to an axis through the benzazepine nitrogen and the benzo ring are more effective as selective dopamine D₁ and D₅ receptor antagonists than benzazepines in which the hydrogen bond donor is pointed away from the axis. Attempts to replace the phenol group in a benzazepine II (X = H₂) with a bioisostere lead to decreased binding to the desired dopamine receptors; an indazolobenzazepine III is an active dopamine D₁ and D₅ receptor antagonist. I (R = H, Me) show improved pharmacokinetic behavior over II (X = CH₂CH₂) in rats; III shows similar pharmacokinetic behavior in rats

to II (X = H₂).

IT 668476-37-7P 668476-46-8P


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of nonracemic benzazepines and naphthazepines containing bioisosteric replacements for a phenol moiety and their activity as selective dopamine D₁/D₅ receptor antagonists and the pharmacokinetic behavior of selected benzazepines)

RN 668476-37-7 CAPLUS

CN Benzimidazo[5,4-d]benzo[g][1]benzazepin-2(1H)-one, 4-chloro-3,6,7,8,8a,9,10,14b-octahydro-8-methyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-46-8 CAPLUS

CN 2H-Benzothiazolo[6,7-d][1]benzazepin-2-one, 4-chloro-3,6,7,8,8a,9,10,14b-octahydro-8-methyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 668476-25-3P 668476-47-9P 847265-03-6P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation of nonracemic benzazepines and naphthazepines containing bioisosteric replacements for a phenol moiety and their activity as selective dopamine D₁/D₅ receptor antagonists and the pharmacokinetic behavior of selected benzazepines)

RN 668476-25-3 CAPLUS

CN Pyrazolo[4,3-g][3]benzazepine, 4-chloro-3,6,7,8,9,10-hexahydro-8-methyl-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)

10/649,495


Absolute stereochemistry.



RN 668476-47-9 CAPLUS

CN 2H-Benzо[g]benzothiazolo[6,7-d][1]benzazепин-2-one, 4-chloro-3,6,7,8,8a,9,10,14b-octahydro-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847265-03-6 CAPLUS

CN Benzimidazo[5,4-d]benzo[g][1]benzazепин-2(1H)-one, 4-chloro-3,6,7,8,8a,9,10,14b-octahydro-, monohydrochloride, (8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 668476-24-2P 668476-44-6P 668476-57-1P

668476-56-2P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of nonracemic benzazepines and naphthazepines containing bioisosteric replacements for a phenol moiety and their activity as selective dopamine D₁/D₅ receptor antagonists and the pharmacokinetic behavior of selected benzazepines)

RN 668476-24-2 CAPLUS

CN Pyrazolo[4,3-g][3]benzazepine, 4-chloro-3,6,7,8,9,10-hexahydro-3,8-dimethyl-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-44-6 CAPLUS

CN 2H-Benzothiazolo[6,7-d][1]benzazepine-2-thione,
4-chloro-3,6,7,8,8a,9,10,14b-octahydro-8-methyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-57-1 CAPLUS

CN 2H-Thiazolo[5,4-g][3]benzazepin-2-one, 4-chloro-3,6,7,8,9,10-hexahydro-8-methyl-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-66-2 CAPLUS

CN Imidazo[4,5-g][3]benzazepin-2(1H)-one, 4-chloro-3,6,7,8,9,10-hexahydro-8-methyl-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 668476-26-4P 668476-29-7P 668476-34-4P
668476-36-6P 668476-38-8P 668476-58-2P
668476-67-3P 668476-68-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)

(preparation of nonracemic benzazepines and naphthazepines containing
bioisosteric replacements for a phenol moiety and their activity as
selective dopamine D₁/D₅ receptor antagonists and the pharmacokinetic
behavior of selected benzazepines)

RN 668476-26-4 CAPLUS

CN Pyrazolo[4,3-g][3]benzazepine, 4-chloro-3,6,7,8,9,10-hexahydro-10-phenyl-,
(10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-29-7 CAPLUS

CN Benz[g]indolo[5,4-d][1]benzazepine, 7-chloro-1,2,2a,3,4,5,8,10c-octahydro-
3,9-dimethyl-, (2aS,10cR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668476-34-4 CAPLUS

CN Benzimidazo[5,4-d]benzo[g][1]benzazepine, 4-chloro-1,6,7,8,8a,9,10,14b-

10/649,495

octahydro-8-methyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-36-6 CAPLUS

CN Benzo[g]benzotriazolo[5,4-d][1]benzazepine, 4-chloro-1,6,7,8,8a,9,10,14b-octahydro-8-methyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-38-8 CAPLUS

CN Benzimidazo[5,4-d]benzo[g][1]benzazepine-2(1H)-thione, 4-chloro-3,6,7,8,8a,9,10,14b-octahydro-8-methyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668476-58-2 CAPLUS

CN 2H-Thiazolo[5,4-g][3]benzazepin-2-one, 4-chloro-3,6,7,8,9,10-hexahydro-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)

10/649,495


Absolute stereochemistry.



RN 668476-67-3 CAPLUS

CN Imidazo[4,5-g][3]benzazepin-2(1H)-one, 4-chloro-3,6,7,8,9,10-hexahydro-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-68-4 CAPLUS

CN Imidazo[4,5-g][3]benzazepine-2(1H)-thione, 4-chloro-3,6,7,8,9,10-hexahydro-8-methyl-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 847265-05-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of nonracemic benzazepines and naphthazepines containing bioisosteric replacements for a phenol moiety and their activity as selective dopamine D₁/D₅ receptor antagonists and the pharmacokinetic behavior of selected benzazepines)

RN 847265-05-8 CAPLUS

CN Benzimidazo[5,4-d]benzo[g][1]benzazepin-2(1H)-one, 4-chloro-3,6,7,8,8a,9,10,14b-octahydro-8-methyl-, monohydrochloride, (8aS,14bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 668476-45-7P 668476-55-9P 668476-56-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of nonracemic benzazepines and naphthazepines containing bioisosteric replacements for a phenol moiety and their activity as selective dopamine D₁/D₅ receptor antagonists and the pharmacokinetic behavior of selected benzazepines)

RN 668476-45-7 CAPLUS

CN 6H-Benzothiazolo[6,7-d][1]benzazepine, 4-chloro-2-(ethylthio)-7,8,8a,9,10,14b-hexahydro-8-methyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-55-9 CAPLUS

CN 2H-Thiazolo[5,4-g][3]benzazepine-2-thione, 4-chloro-3,6,7,8,9,10-hexahydro-8-methyl-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/649,495

RN 668476-56-0 CAPLUS

CN 6H-Thiazolo[5,4-g][3]benzazepine, 4-chloro-2-(ethylthio)-7,8,9,10-tetrahydro-8-methyl-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:




60

THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/649,495

L24 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:203836 CAPLUS
DOCUMENT NUMBER: 140:235618
TITLE: Preparation of benzazepine derivatives as selective
D1/D5 receptor antagonists for the treatment of
obesity and CNS disorders
INVENTOR(S): Wu, Wen-Lian; Burnett, Duane A.; Greenlee, William J.;
Sasikumar, Thavalakulam K.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020442	A1	20040311	WO 2003-US26878	20030827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2495879	AA	20040311	CA 2003-2495879	20030827
AU 2003262926	A1	20040319	AU 2003-262926	20030827
US 2004058906	A1	20040325	US 2003-649495	20030827
EP 1537115	A1	20050608	EP 2003-791865	20030827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501244	T2	20060112	JP 2004-531584	20030827
PRIORITY APPLN. INFO.:			US 2002-406856P	P 20020829
			WO 2003-US26878	W 20030827
OTHER SOURCE(S):	MARPAT	140:235618		
GI				



AB The title compds. I and II [R1 = H, alkyl, allyl, cycloalkyl, cycloalkyl(alkyl); R2 = H, halo, alkyl, alkylthio, alkylsulfonyl, OH, alkoxy, CF₃, CF₃O, aryl, CHO, NO₂, substituted amines, CN, etc.; G = H, halo, alkyl, alkylthio, NO₂, CN, OH, alkoxy, alkylsulfinyl, alkylsulfonyl, CF₃, or CF₃O; X = CH, C(alkyl), CCF₃, or N; Y = CH, C(alkyl) or N; Z = NH, N(alkyl), S, or O; V = CH₂; n = 0-2, when n = 0, the carbons to which (V)_n is shown connected are not linked to each other but are linked to hydrogen] were prepared as selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders. For example, treatment of (6aS,13bR)-12,13-diamino-11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepine (preparation given) with thiocarbonyldiimidazole gave compound III. The latter is a novel antagonist for D1 receptor with K_i = 40 nM.

IT 668476-46-8P 668476-57-1P 668476-64-0P


668476-66-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzazepine derivs. as selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders)

RN 668476-46-8 CAPLUS

CN 2H-Benzothiazolo[6,7-d][1]benzazepin-2-one, 4-chloro-3,6,7,8,8a,9,10,14b-octahydro-8-methyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-57-1 CAPLUS

CN 2H-Thiazolo[5,4-g][3]benzazepin-2-one, 4-chloro-3,6,7,8,9,10-hexahydro-8-methyl-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-64-0 CAPLUS

CN Benzimidazo[5,4-d]benzo[g][1]benzazepin-2(1H)-one, 11-bromo-4-chloro-3,6,7,8,8a,9,10,14b-octahydro-8-methyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-66-2 CAPLUS

CN Imidazo[4,5-g][3]benzazepin-2(1H)-one, 4-chloro-3,6,7,8,9,10-hexahydro-8-methyl-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 668476-25-3P 668476-26-4P 668476-29-7P
 668476-34-4P 668476-36-6P 668476-38-8P
 668476-39-9P 668476-47-9P 668476-48-0P
 668476-58-2P 668476-65-1P 668476-67-3P
 668476-68-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzazepine derivs. as selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders)

RN 668476-25-3 CAPPLUS

CN Pyrazolo[4,3-g][3]benzazepine, 4-chloro-3,6,7,8,9,10-hexahydro-8-methyl-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-26-4 CAPPLUS

CN Pyrazolo[4,3-g][3]benzazepine, 4-chloro-3,6,7,8,9,10-hexahydro-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-29-7 CAPPLUS

CN Benz[g]indolo[5,4-d][1]benzazepine, 7-chloro-1,2,2a,3,4,5,8,10c-octahydro-3,9-dimethyl-, (2aS,10cR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-34-4 CAPLUS

CN Benzimidazo[5,4-d]benzo[g][1]benzazepine, 4-chloro-1,6,7,8,8a,9,10,14b-octahydro-8-methyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-36-6 CAPLUS

CN Benzo[g]benzotriazolo[5,4-d][1]benzazepine, 4-chloro-1,6,7,8,8a,9,10,14b-octahydro-8-methyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-38-8 CAPLUS

CN Benzimidazo[5,4-d]benzo[g][1]benzazepine-2(1H)-thione, 4-chloro-3,6,7,8,8a,9,10,14b-octahydro-8-methyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-39-9 CAPLUS

CN Benzimidazo[5,4-d]benzo[g][1]benzazepin-2(1H)-one, 4-chloro-3,6,7,8,8a,9,10,14b-octahydro-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-47-9 CAPLUS

CN 2H-Benz[b]benzothiazolo[6,7-d][1]benzazepin-2-one, 4-chloro-3,6,7,8,8a,9,10,14b-octahydro-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-48-0 CAPLUS

CN Benzimidazo[5,4-d]benzo[g][1]benzazepin-2(1H)-one, 4-chloro-3,6,7,8,8a,9,10,14b-octahydro-8-methyl-11-phenyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-58-2 CAPLUS

CN 2H-Thiazolo[5,4-g][3]benzazepin-2-one, 4-chloro-3,6,7,8,9,10-hexahydro-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-65-1 CAPLUS

CN Benzimidazo[5,4-d]benzo[g][1]benzazepin-2(1H)-one, 11-bromo-4-chloro-3,6,7,8,8a,9,10,14b-octahydro-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-67-3 CAPLUS

CN Imidazo[4,5-g][3]benzazepin-2(1H)-one, 4-chloro-3,6,7,8,9,10-hexahydro-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-68-4 CAPLUS

CN Imidazo[4,5-g][3]benzazepine-2(1H)-thione, 4-chloro-3,6,7,8,9,10-hexahydro-8-methyl-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 668476-24-2P 668476-37-7P 668476-44-6P
668476-45-7P 668476-55-9P 668476-56-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzazepine derivs. as selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders)

RN 668476-24-2 CAPLUS

CN Pyrazolo[4,3-g][3]benzazepine, 4-chloro-3,6,7,8,9,10-hexahydro-3,8-dimethyl-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-37-7 CAPLUS

CN Benzimidazo[5,4-d]benzo[g][1]benzazepin-2(1H)-one, 4-chloro-3,6,7,8,8a,9,10,14b-octahydro-8-methyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-44-6 CAPLUS

CN 2H-Benzothiazolo[6,7-d][1]benzazepine-2-thione,
4-chloro-3,6,7,8,8a,9,10,14b-octahydro-8-methyl-, (8aS,14bR)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 668476-45-7 CAPLUS

CN 6H-Benzothiazolo[6,7-d][1]benzazepine, 4-chloro-2-(ethylthio)-
7,8,8a,9,10,14b-hexahydro-8-methyl-, (8aS,14bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-55-9 CAPLUS

CN 2H-Thiazolo[5,4-g][3]benzazepine-2-thione, 4-chloro-3,6,7,8,9,10-hexahydro-
8-methyl-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 668476-56-0 CAPLUS

CN 6H-Thiazolo[5,4-g][3]benzazepine, 4-chloro-2-(ethylthio)-7,8,9,10-tetrahydro-8-methyl-10-phenyl-, (10R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT